An Overview of Polyethylene Glycol with Lactulose as Additional Therapy in the Treatment of Hepatic Encephalopathy

Background: Hepatic encephalopathy (HE) is a condition marked by compromised brain function resulting from liver dysfunction, often linked to acute liver failure or cirrhosis, with notable morbidity and mortality. Lactulose has been the conventional treatment, but polyethylene glycol (PEG) has garnered interest from several investigators Aim: To provide an overview of PEG as add on therapy in the Management of HE. This review aims to function as a resource for clinicians, providing evidence on therapeutic decisions of Polyethylene glycol in hepatic encephalopathy. Method: We conducted a comphrensive search across five prominent databases, specifically Scopus, Web of Science, PubMed, Embase, and Cochrane Library.. Moreover, additional records were identified through alternative channels, such as Google Scholar Results: According to the findings, polyethylene glycol (PEG) has a beneficial effect on the management of hepatic encephalopathy (HE). Five randomized studies involving a total of 300 patients were conducted. PEG therapy was found to have a substantial benefit in terms of improving clinical efficacy and reducing hospital stays. Conclusion: From the results show that PEG is a successful treatment for HE. When PEG is used in place of lactulose, shorter stays are possible without raising the frequency of unfavourable events, and HE resolution can occur more quickly during the first twenty-four hours.